Literatur
- 1
Braunstein J B, Hausfeld J, London A.
Economics of reducing menstruation with trimonthly-cycle oral contraceptive therapy:
comparison with standard-cycle regimens.
Obstet Gynecol.
2003;
102
699-708
- 2
Cote I, Jacobs P, Cumming D.
Work loss associated with increased menstrual loss in the United States.
Obstet Gynecol.
2002;
100
683-687
- 3
Jones G L, Kennedy S H, Jenkinson C.
Health-related quality of life measurement in women with common benign gynecologic
conditions: a systematic review.
Am J Obstet Gynecol.
2002;
187
501-511
- 4
Lichten E M, Bombard J.
Surgical treatment of primary dysmenorrhea with laparoscopic uterine nerve ablation.
J Reprod Med.
1987;
32
37-41
- 5 Bravermann P K, Neinstein L S. Dysmenorrhea and Premenstrual Syndrome in Adolescent
Health Care: A Practical Guide. Philadelphia; Lippincott Williams & Wilkins 2002
- 6
Dawood M Y.
Dysmenorrhea.
Clin Obstet Gynecol.
1990;
33
168-178
- 7
Rosenwaks Z, Seegar-Jones G.
Menstrual pain: its origin and pathogenesis.
J Reprod Med.
1980;
25
207-212
- 8
Bieglmayer C, Hofer G, Kainz C, Reinthaller A, Kopp B, Janisch H.
Concentrations of various arachidonic acid metabolites in menstrual fluid are associated
with menstrual pain and are influenced by hormonal contraceptives.
Gynecol Endocrinol.
1995;
9
307-312
- 9
Stromberg P, Akerlund M, Forsling M L, Granstrom E, Kindahl H.
Vasopressin and prostaglandins in premenstrual pain and primary dysmenorrhea.
Acta Obstet Gynecol Scand.
1984;
63
533-538
- 10 Melzack R, Katz J.
Pain measurement in persons in pain. Wall PD, Melzack R Textbook of Pain. London; Churchill Livingstone 1994
- 11
Moos R H.
The development of a menstrual distress questionnaire.
Psychosom Med.
1968;
30
853-867
- 12
Chesney M A, Tasto D L.
The development of the menstrual symptom questionnaire.
Behav Res Ther.
1975;
13
237-244
- 13
Marjoribanks J, Proctor M L, Farquhar C.
Nonsteroidal anti-inflammatory drugs for primary dysmenorrhea.
Cochrane Database Syst Rev.
2003;
CD001751
- 14
Daniels S E, Talwalker S, Torri S, Snabes M C, Recker D P, Verburg K M.
Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary
dysmenorrhea.
Obstet Gynecol.
2002;
100
350-358
- 15
Proctor M L, Roberts H, Farquhar C M.
Combined Oral Contraceptive Pill (Ocp) as Treatment for Primary Dysmenorrhea.
Cochrane Database Syst Rev.
2001;
CD002120
- 16
Wiegratz I, Kuhl H.
Long-cycle treatment with oral contraceptives.
Drugs.
2004;
64
2447-2462
- 17
Vercellini P, Frontino G, De Giorgi O, Pietropaolo G, Pasin R, Crosignani P G.
Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea
that does not respond to a cyclic pill regimen.
Fertil Steril.
2003;
80
560-563
- 18 Lundstrom V.
Endocrine pathophysiology of primary dysmenorrhea. Dawood MY, McGuire JL, Demers LM Premenstrual Syndrome and Dysmenorrhea. Baltimore;
Urban & Schwarzenberg 1985
- 19
Proctor M L, Smith C A, Farquhar C M, Stones R W.
Transcutaneous electrical nerve stimulation and acupuncture for primary dysmenorrhea.
Cochrane Database Syst Rev.
2002;
CD002123
- 20
Wilson M L, Murphy P A.
Herbal and dietary therapies for primary and secondary dysmenorrhea.
Cochrane Database Syst Rev.
2001;
CD002124
- 21
Akin M D, Weingand K W, Hengehold D A, Goodale M B, Hinkle R T, Smith R P.
Continuous low-level topical heat in the treatment of dysmenorrhea.
Obstet Gynecol.
2001;
97
343-349
- 22
Golomb L M, Solidum A A, Warren M P.
Primary dysmenorrhea and physical activity.
Med Sci Sports Exerc.
1998;
30
906-909
- 23
Mortola J F, Girton L, Yen S S.
Depressive episodes in premenstrual syndrome.
Am J Obstet Gynecol.
1989;
161
1682-1687
- 24
Reid R L.
Premenstrual syndrome.
N Engl J Med.
1991;
324
1208-1210
- 25
Mortola J F.
Premenstrual syndrome - pathophysiologic considerations.
N Engl J Med.
1998;
338
256-257
- 26
Endicott J.
History, evolution, and diagnosis of premenstrual dysphoric disorder.
J Clin Psychiatry.
2000;
61 (Suppl 12)
5-8
- 27
Greene R, Dalton K.
The premenstrual syndrome.
Br Med J.
1953;
1
1007-1014
- 28
Munday M, Brush M G, Taylor R W.
Progesterone and aldosterone levels in the premenstrual tension syndrome (proceedings).
J Endocrinol.
1977;
73
21P-22P
- 29
Rapkin A J, Morgan M, Goldman L, Brann D W, Simone D, Mahesh V B.
Progesterone metabolite allopregnanolone in women with premenstrual syndrome.
Obstet Gynecol.
1997;
90
709-714
- 30
Schmidt P J, Nieman L K, Danaceau M A, Adams L F, Rubinow D R.
Differential behavioral effects of gonadal steroids in women with and in those without
premenstrual syndrome.
N Engl J Med.
1998;
338
209-216
- 31
Dimmock P W, Wyatt K M, Jones P W, O'Brien P M.
Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic
review.
Lancet.
2000;
356
1131-1136
- 32
Tan K S.
Premenstrual asthma: epidemiology, pathogenesis and treatment.
Drugs.
2001;
61
2079-2086
- 33
Maguire J L, Stell B M, Rafizadeh M, Mody I.
Ovarian cycle-linked changes in GABA (A) receptors mediating tonic inhibition alter
seizure susceptibility and anxiety.
Nat Neurosci.
2005;
8
797-804
- 34
MacGregor E A, Frith A, Ellis J, Aspinall L.
Predicting menstrual migraine with a home-use fertility monitor.
Neurology.
2005;
64
561-563
- 35
Johnson S R.
Premenstrual syndrome, premenstrual dysphoric disorder, and beyond: a clinical primer
for practitioners.
Obstet Gynecol.
2004;
104
845-859
- 36
Parry B L, Newton R P.
Chronobiological basis of female-specific mood disorders.
Neuropsychopharmacology.
2001;
25
S102-S108
- 37
Rossignol A M, Bonnlander H.
Caffeine-containing beverages, total fluid consumption, and premenstrual syndrome.
Am J Public Health.
1990;
80
1106-1110
- 38
Freeman E W, Stout A L, Endicott J, Spiers P.
Treatment of premenstrual syndrome with a carbohydrate-rich beverage.
Int J Gynecol Obstet.
2002;
77
253-254
- 39
Thys-Jacobs S, Starkey P, Bernstein D, Tian J.
Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual
symptoms. Premenstrual Syndrome Study Group.
Am J Obstet Gynecol.
1998;
179
444-452
- 40
Facchinetti F, Borella P, Sances G, Fioroni L, Nappi R E, Genazzani A R.
Oral magnesium successfully relieves premenstrual mood changes.
Obstet Gynecol.
1991;
78
177-181
- 41
Berger D, Schaffner W, Schrader E, Meier B, Brattstrom A.
Efficacy of Vitex agnus castus L. extract Ze 440 in patients with pre-menstrual syndrome
(PMS).
Arch Gynecol Obstet.
2000;
264
150-153
- 42
Freeman E, Rickels K, Sondheimer S J, Polansky M.
Ineffectiveness of progesterone suppository treatment for premenstrual syndrome.
JAMA.
1990;
264
349-353
- 43
Wyatt K, Dimmock P, Jones P, Obhrai M, O'Brien S.
Efficacy of progesterone and progestogens in management of premenstrual syndrome:
systematic review.
BMJ.
2001;
323
776-780
- 44
Freeman E W, Kroll R, Rapkin A, Pearlstein T, Brown C, Parsey K, Zhang P, Patel H,
Foegh M.
Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric
disorder.
J Womens Health Gend Based Med.
2001;
10
561-569
- 45
Steiner M, Steinberg S, Stewart D, Carter D, Berger C, Reid R, Grover D, Streiner D.
Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual
Dysphoria Collaborative Study Group.
N Engl J Med.
1995;
332
1529-1534
- 46
Yonkers K A, Halbreich U, Freeman E, Brown C, Endicott J, Frank E, Parry B, Pearlstein T,
Severino S, Stout A, Stone A, Harrison W.
Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment.
A randomized controlled trial. Sertraline premenstrual dysphoric collaborative study
group.
JAMA.
1997;
278
983-988
- 47
Wyatt K M, Dimmock P W, O'Brien P M.
Selective serotonin reuptake inhibitors for premenstrual syndrome.
Cochrane Database Syst Rev.
2002;
CD001396
- 48
Wyatt K M, Dimmock P W, Ismail K M, Jones P W, O'Brien P M.
The effectiveness of GnRHa with and without “add-back” therapy in treating premenstrual
syndrome: a meta analysis.
BJOG.
2004;
111
585-593
Dr. med. Barbara Sonntag
Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
Universitätsklinikum Münster
Albert-Schweitzer-Straße 33
48129 Münster
Email: sonntag@uni-muenster.de
